Investors have pared 30.0% from HeartWare International (NSDQ:HTWR) since the company said yesterday that it may not be able to resume a trial of its MVAD implantable heart pump next month, as was expected.
Framingham, Mass.-based HeartWare, which put a hold on enrollment in its CE Mark trial Sept. 9 due to controller manufacturing and software issues, said it began investigating reports of adverse events in certain trial subjects, but didn’t explain the nature of the events other than to say that they’re “typical of those seen in other clinical trials for ventricular assist devices.”
Help employers find you! Check out all the jobs and post your resume.
